CYP2C19 rs114302844: Understanding Your Genetic Variant
The rs114302844 variant is a specific genetic change located within the CYP2C19 gene. This gene is responsible for producing an enzyme that helps the body process, or metabolize, a wide range of therapeutic drugs.
What each genotype means
Normal enzyme activity
This genotype represents the most common form of the CYP2C19 gene, typically associated with normal metabolism of medications like clopidogrel. Individuals with this profile are generally expected to process these drugs at a standard rate. Please discuss your medication response and any necessary dosing with your clinician or pharmacist.
This is the most common genotype found across all global populations.
Reduced enzyme activity
This genotype includes one copy of a variant that may lead to reduced CYP2C19 enzyme activity, which can influence how your body metabolizes certain drugs. Research suggests this may result in lower levels of active medication in your system compared to those with the GG genotype. Please consult your healthcare provider or pharmacist to determine if this impacts your specific treatment plan.
This genotype is observed at varying frequencies depending on ancestry, generally being less common than the homozygous normal genotype.
Significantly reduced enzyme activity
This genotype indicates the presence of two copies of the variant, which is associated with significantly reduced or absent CYP2C19 enzyme function. This may lead to decreased effectiveness of medications that require this enzyme for activation, such as clopidogrel. It is important to discuss this genetic finding with your doctor or pharmacist to ensure your medication therapy is appropriate for your metabolism.
This genotype is rare in the general population, with frequency varying significantly by ethnic and ancestral background.
What is the rs114302844 Variant?
The rs114302844 variant is a single nucleotide polymorphism (SNP) found within the CYP2C19 gene. In genomics, a SNP represents a variation at a single position in the DNA sequence. This specific variant is cataloged in public databases as part of the ongoing effort to map human genetic diversity. Because the CYP2C19 gene is highly polymorphic, meaning it contains many different variations, researchers study these specific sites to understand how they might alter the structure or function of the resulting protein. While some variants in this gene are well-characterized for their impact on drug metabolism, others like rs114302844 are still being investigated to determine their precise clinical significance. It is important to view this variant as one small piece of a much larger genetic puzzle that influences how our bodies interact with the chemical compounds we ingest.
The Role of the CYP2C19 Gene
The CYP2C19 gene provides the instructions for creating the cytochrome P450 2C19 enzyme. This enzyme is primarily located in the liver and acts as a biological catalyst, breaking down various substances so they can be cleared from the body. It is responsible for metabolizing a significant number of commonly prescribed medications, including certain antidepressants, proton pump inhibitors used for acid reflux, and antiplatelet drugs like clopidogrel. When the CYP2C19 gene functions normally, the enzyme processes these drugs at a predictable rate. However, genetic variations can lead to enzymes that are either less active, completely inactive, or sometimes more active than usual. These differences can change the concentration of a drug in the bloodstream, potentially affecting how well a medication works or the likelihood of experiencing side effects.
Research and Evidence Strength
Current research into rs114302844 is categorized as having limited evidence regarding its clinical impact. While the broader CYP2C19 gene is a major focus of pharmacogenomics—the study of how genes affect drug response—not every individual variant has been definitively linked to a specific change in enzyme activity. Many variants in this gene are rare, making it difficult for scientists to gather enough data to draw firm conclusions about their effects. While some well-known variants like CYP2C19*2 or CYP2C19*17 have clear, established roles in drug metabolism, rs114302844 does not currently have the same level of clinical validation. Consequently, it is not typically used in standard clinical decision-making. Researchers continue to study such variants to determine if they contribute to the 'missing heritability' of drug response, but for now, the functional consequences of this specific SNP remain an area of active scientific inquiry rather than established medical fact.
Population Frequency
The rs114302844 variant is considered rare across most human populations. Genetic frequency can vary significantly depending on ancestral background, and large-scale genomic databases are essential for tracking these differences. Because this variant is rare, it is not frequently encountered in the general population, which contributes to the limited amount of clinical data available. Understanding the frequency of such variants is a key goal of population genetics, as it helps researchers identify which groups might be more likely to carry specific genetic traits. However, because the frequency is low, it is unlikely to be a primary factor in the drug response profiles of the vast majority of individuals. As more people participate in genomic research, our understanding of the distribution of this variant across different global populations will continue to improve.
What You Can Do With This Information
If you have received information about the rs114302844 variant, it is important to understand that this is not a medical diagnosis. Genetic variants are simply biological data points, and they do not dictate your health outcomes on their own. Because the evidence for this specific variant is limited, it should not be used to make decisions about your medications. If you are concerned about how a specific drug is affecting you, or if you are interested in how your genetics might influence your treatment, the best course of action is to speak with your healthcare provider or a pharmacist. They can review your medical history, current medications, and any relevant genetic testing results to provide personalized guidance. Never change your medication dosage or stop taking a prescribed drug based on genetic information without consulting a qualified medical professional.
How common is this variant?
The rs114302844 variant is classified as rare, with low frequency observed across most global ancestral populations.
Frequently asked questions
Is rs114302844 a cause for concern?
No, this variant is not a medical diagnosis. It is a common type of genetic variation, and because the evidence regarding its impact is limited, it is not currently used to predict health outcomes.
Should I change my medication based on this variant?
Absolutely not. You should never alter your medication regimen based on genetic data without consulting your doctor or pharmacist, as they must consider your entire medical history.
Where can I find more information about CYP2C19?
You can explore resources like MedlinePlus Genetics or the Clinical Pharmacogenetics Implementation Consortium (CPIC) for reliable, evidence-based information on how genes like CYP2C19 affect drug metabolism.
Why is the evidence for this variant limited?
Scientific evidence is built through large-scale studies. Because this variant is rare, there is less data available to confirm its specific functional effects compared to more common variants.
Sources & further reading
Educational information only, last refreshed 9/15/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs114302844?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in CYP2C19
Defines the CYP2C19*17 increased function allele, conferring rapid or ultrarapid metabolism for CPIC-actionable drugs including clopidogrel, PPIs, and SSRIs.
The CYP2C19*2 loss-of-function splicing defect results in impaired biotransformation of prodrugs including clopidogrel and altered clearance of proton pump inhibitors and select antidepressants.
Variant in the CYP2C19 locus associated with altered metabolism of clopidogrel and proton-pump inhibitors.
Defines the CYP2C19*8 loss-of-function variant (c.358T>C, p.Trp120Arg) which results in no enzymatic activity and impaired metabolism of CYP2C19 substrates.
Defines the CYP2C19*4 allele caused by an ATG start codon alteration that abolishes translation, resulting in reduced or absent drug metabolism capacity.
Defines the non-functional CYP2C19*3 null allele resulting from a premature stop codon, leading to poor metabolism of drugs such as clopidogrel, escitalopram, and proton pump inhibitors.